Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers

Although the medical treatment of colorectal cancer has evolved greatly in the last years, a significant portion of early-stage patients develops recurrence after therapies. The current clinical trials are directed to evaluate new drug combinations and treatment schedules. By the use of patient-deri...

Descripción completa

Detalles Bibliográficos
Autores principales: Bon, Giulia, Loria, Rossella, Amoreo, Carla Azzurra, Verdina, Alessandra, Sperduti, Isabella, Mastrofrancesco, Arianna, Soddu, Silvia, Diodoro, Maria Grazia, Mottolese, Marcella, Todaro, Matilde, Stassi, Giorgio, Milella, Michele, De Maria, Ruggero, Falcioni, Rita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5752456/
https://www.ncbi.nlm.nih.gov/pubmed/29312543
http://dx.doi.org/10.18632/oncotarget.11400

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5752456/
https://www.ncbi.nlm.nih.gov/pubmed/29312543
http://dx.doi.org/10.18632/oncotarget.11400

Ejemplares similares